Market Dynamics Related To The Development And Commercialization Of Peptides

Matt Bio is Chief Scientific Officer at Cambrex and President of Snapdragon Chemistry, based in Waltham, MA. A founding member of Snapdragon, he holds a Ph.D. in Chemistry and brings more than 30 years of academic and industry experience in the life sciences, including roles at Rohm & Haas, Merck Research Laboratories, and Amgen.

He leads Cambrex's scientific innovation strategy across continuous manufacturing, complex synthetic process development, AI, and automation, with expertise spanning process chemistry, manufacturing technologies for synthetic–biologic hybrid molecules, solid- and liquid-phase peptide synthesis, and oligonucleotide process development.

Asked about the market dynamics shaping peptide development and commercialization, Bio points to a capacity bottleneck: solid-phase synthesis is concentrated in a small number of facilities that are expensive and slow to ramp, leaving many peptides in short supply. A liquid-phase approach breaks that dependence on specialized reactors, opening access to conventional capacity worldwide at scales reaching tens of thousands of liters.